Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KAN-ONCO-07
- Development stage
- Preclinical
- Lead developer
- Kantify
- Modality
- Small Molecules
01
Overview
KAN-ONCO-07 is a preclinical-stage small molecule drug candidate being developed by Kantify for the treatment of various cancers (Pan Cancer). Discovered using Kantify's proprietary Sapian™ AI platform, the program is designed to modulate multiple novel oncology targets. As of early 2024, the program is fully owned by Kantify and is in the preclinical development phase, focusing on hit discovery and lead optimization. While the specific biological targets and detailed mechanism of action remain proprietary, the program represents a key part of Kantify's AI-driven oncology pipeline aimed at identifying first-in-class or best-in-class therapies for broad cancer indications.
Beyond the preview
Go deeper on KAN-ONCO-07.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KAN-ONCO-07.